Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082914 | 1.00 | GRIK1 (0.35) | GRIK1GRIK2MEN1GAAKMT2A | |
| SCHEMBL6693217 | 0.92 | CTSK (0.34) | MEN1GAAKMT2ACYP2C19SMN1; SMN2 | |
| SCHEMBL8183510 | 0.87 | SMN1; SMN2 (0.32) | CYP2C19SMN1; SMN2CTSKTSHRCYP3A4 | |
| SCHEMBL7601657 | 0.87 | SMN1; SMN2 (0.32) | CYP2C19SMN1; SMN2CTSKTSHRCYP3A4 | |
| SCHEMBL20241539 | 0.85 | CA12 (0.35) | MEN1KMT2ACYP2C19SMN1; SMN2CTSK | |
| SCHEMBL9650643 | 0.84 | SMN1; SMN2 (0.41) | MEN1KMT2ACYP2C19SMN1; SMN2CTSK | |
| SCHEMBL27664481 | 0.84 | SMN1; SMN2 (0.31) | CYP2C19SMN1; SMN2CTSKTSHRCYP3A4 | |
| SCHEMBL8198261 | 0.82 | CTSK (0.37) | MEN1GAAKMT2ACTSKAAK1 | |
| SCHEMBL14349106 | 0.82 | — | — | |
| SCHEMBL15619396 | 0.81 | GRIK1 (0.33) | GRIK1GRIK2MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505779-B2 | Tacrolimus analogues, a neuroprotective composition comprising the same, an immunosuppressive composition comprising the same, a method for preparing the same, and a mutant for producing the same | INTRON BIOTECHNOLOGY, INC. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-9505779-B2 | Tacrolimus analogues, a neuroprotective composition comprising the same, an immunosuppressive composition comprising the same, a method for preparing the same, and a mutant for producing the same | INTRON BIOTECHNOLOGY, INC. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-20130230559-A1 | NOVEL TACROLIMUS ANALOGUES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME | Ewha University - Industry Collaboration Foundatio (KR) | 2013-09-05 | — | — | US | disclosed |
| US-20130230559-A1 | NOVEL TACROLIMUS ANALOGUES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME | Ewha University - Industry Collaboration Foundatio (KR) | 2013-09-05 | — | — | US | disclosed |
| WO-2012026665-A1 | NOVEL TACROLIMUS DERIVATIVES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-01 | — | — | WO | disclosed |
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-0024965-B1 | FLUORINATED METHYL BETA-ALANINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-04-27 | — | — | EP | disclosed |
| US-4375477-A | ENZYME INHIBITORS | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-03-01 | — | — | US | disclosed |
| EP-0024965-A1 | Fluorinated methyl beta-alanine derivatives, their preparation and pharmaceutical compositions containing them | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | GRIK1 1402/4885GRIK2 1764/4885MEN1 808/4885 |
| US-20130230559-A1 | NOVEL TACROLIMUS ANALOGUES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME | CTSA, TPSAB1, ARSA | GRIK1 1485/4885GRIK2 1769/4885MEN1 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.